PRODUCTS

BAYTRIL

Baytril is a broad-spectrum fluoroquinolone antibiotic commonly used in veterinary medicine to treat bacterial infections in animals, particularly in poultry, cattle, and companion animals such as dogs and cats.
Baytril acts by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, leading to rapid bacterial cell death.
While highly effective, Baytril's use is regulated due to concerns about antimicrobial resistance and the potential for cross-resistance to other fluoroquinolones important in human medicine.

CAS Number: 93106-60-6
EC Number: 618-571-2
Molecular Formula: C19H22FN3O3
Molecular Weight: 359.40 g/mol

Synonyms: Enrofloxacin, 93106-60-6, Enrofloxacine, Enrofloxacino, CFPQ, Enrofloxacinum, endrofloxicin, 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, ERFX, Enrofloxacinum [Latin], HSDB 6952, UNII-3DX3XEK1BN, 3DX3XEK1BN, NSC-758616, BRN 5307824, Enrofloxacin for veterinary use, CCRIS 8214, DTXSID1045619, CHEBI:35720, DTXCID9025619, Enrofloxacin [USAN:USP:INN:BAN], 1,4-Dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-3-quinolinecarboxylic acid, NSC 758616, Enrofloxacinum (Latin), ENROFLOXACIN (MART.), ENROFLOXACIN [MART.], 3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-, ENROFLOXACIN (USP-RS), ENROFLOXACIN [USP-RS], ENROFLOXACIN (USP IMPURITY), ENROFLOXACIN [USP IMPURITY], Enrofloxacin (USAN:USP:INN:BAN), ENROFLOXACIN (USP MONOGRAPH), ENROFLOXACIN [USP MONOGRAPH], Enrofloxacin base, ENROFLOXACIN FOR VETERINARY USE (EP IMPURITY), ENROFLOXACIN FOR VETERINARY USE (EP MONOGRAPH), ENROFLOXACIN FOR VETERINARY USE [EP IMPURITY], ENROFLOXACIN FOR VETERINARY USE [EP MONOGRAPH], Quellaxcin, Enroflox, Enroquin, Enrosite, Tenotryl, Zobuxa, EnroMed, EnrositeFlavored, FluroxinFlavored, EnrofloxacinFlavored, Enroflox 100, EnroMed 100, Enroquin Antibacterial, SolutionKitsEnrofloxacin, Enroflox Chewable Tablets, ENROFLOXACIN 100, Fluroxinfor Dogs 2.27%, 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-Fluoro-1,4-Dihydro-4-Oxo-3-Quinolonecarboxylic Acid, Enrofloxacin Flavored Tablets, Baytril Soft Chewable Tablets, Baytril 100 Injectable Solution, Enroflox Injection for Dogs 2.27%, Baytril Antibacterial Injectable Solution, Enrofloxacin Antibacterial Injectable Solution, Baytril Antibacterial Tablets, Baytril Taste Tabs Antibacterial Tablets, 1,4-Dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-3-quinolinecarboxyl acid, 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxyl acid, Baytril, BAY VP 2674, MFCD00792463, Enroxil, Baytril (TN), N-Ethylciprofloxacin, 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-, MLS000069441, BAY Vp 2674, PD160788, NCGC00018143-04, CPD000059011, SMR000059011, 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-quinoline-3-carboxylic acid, Enrofloxacine [French], Enrofloxacino [Spanish], Bay-Vp-2674, 1-cyclopropyl-7-(4-ethylpiperazinyl)-6-fluoro-4-oxohydroquinoline-3-carboxylic acid, 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic Acid, CAS-93106-60-6, Enrofloxacin [USAN:BAN:INN], Baytril (veterinary), Enrofloxacin (Standard), Opera_ID_1106, Enrofloxacin (USP/INN), ENROFLOXACIN [MI], Enrofloxacin (USAN/INN), ENROFLOXACIN [INN], ENROFLOXACIN [HSDB], ENROFLOXACIN [USAN], MLS001076496, MLS001424169, CHEMBL15511, SCHEMBL149150, SPECTRUM1503721, GTPL13668, HY-B0502R, ENROFLOXACIN [GREEN BOOK], MSK4107, HMS2052O09, HMS2090E12, HMS2093I21, HMS2234M11, HMS3373P14, HMS3394O09, HMS3715B18, HMS5087O14, Pharmakon1600-01503721, ALBB-030792, BCP15457, HY-B0502, Enrofloxacin, >=98.0% (HPLC), Tox21_110831, BBL009982, DL-384, NSC758616, s3059, SBB012586, STK711109, AKOS005530685, BAY-Vp2674, PD160788, Tox21_110831_1, AC-7614, AE22674, CCG-101102, DB11404, KS-5010, NC00352, NCGC00018143-01, NCGC00018143-02, NCGC00018143-03, NCGC00018143-05, NCGC00021632-03, PD160788, ST072197, SY052755, SBI-0206725.P001, DB-057368, E0786, Enrofloxacin 1000 microg/mL in Acetonitrile, NS00010889, D02473, F81544, AB00384269-16, AB00384269_17, AB00384269_18, Enrofloxacin, VETRANAL(TM), analytical standard, Q414413, SR-01000000045, SR-01000000045-3, BRD-K76534306-001-11-0, BRD-K76534306-001-21-9, BRD-K76534306-001-22-7, F2173-0641, 1-Cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1, Enrofloxacin, European Pharmacopoeia (EP) Reference Standard, Enrofloxacin, United States Pharmacopeia (USP) Reference Standard, Enrofloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard, Enrofloxacin, Pharmaceutical Secondary Standard, Certified Reference Material, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-quinoline-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-quinolinecarboxylic acid, 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3- quinolonecarboxylic acid, 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, 9CI, 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, CFPQ, Bay vp 2674, 1-CYCLOPROPYL-7-(4-ETHYLPIPERAZINO)-6-FLUORO-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXYLIC ACID, Enrofloxacin, Enrofloxacin HCl, Enrofloxacine, Enorfloxacin, Enorofloxacin hydrochloride, Baytril

Baytril is effective against a wide range of Gram-negative and Gram-positive bacteria, including pathogens responsible for respiratory, urinary, skin, and gastrointestinal infections.
Baytril is typically administered orally, by injection, or as medicated feed or water, depending on the species and condition being treated.

While highly effective, Baytril's use is regulated due to concerns about antimicrobial resistance and the potential for cross-resistance to other fluoroquinolones important in human medicine.
Because of this, withdrawal periods are strictly enforced in food-producing animals to ensure consumer safety.

Baytril's potent bactericidal action, including against resistant strains, makes Baytril effective—but it requires cautious handling due to respiratory sensitization, aquatic toxicity, and cartilage/testis toxicity upon long-term exposure.
Baytril is regulated and contraindicated in some animal sectors, and strict PPE and disposal protocols are highly recommended.

Baytril is a veterinary-grade fluoroquinolone antibiotic (CAS 93106‑60‑6, EC 618‑911‑2), widely used for broad-spectrum bacterial infections in animals.
Baytril is a synthetic chemotherapeutic agent from the class of the quinolone carboxylic acid derivatives.

Baytril has antibacterial activity against a broad spectrum of Gram-negative and Gram-positive bacteria.
Baytril is rapidly absorbed from the digestive tract, penetrating into all measured body tissues and fluids.
Baytril is a fluoroquinolone, broad-spectrum antibiotic which is well tolerated in birds and useful for treating a wide range of bacterial infections.

Baytril is the veterinary-labeled form of ciprofloxacin, which is the equivalent drug used in humans.
In the United States, Baytril is available by prescription only, meaning that you will need to obtain it through your veterinarian who will prescribe it "extra-label" to poultry kept as pets.

Since this drug is a fluoroquinolone-class antibiotic, Baytril is not approved for use in birds who are not kept as pets.
Baytril is bactericidal at low concentrations against a broad spectrum of Gram-negative and Gram-positive bacteria, as well as Mycoplasma and Chlamydia spp.

Baytril is rapidly absorbed in the gastrointestinal tract, bones, and central nervous system.
A single intramuscular injection of Baytril at 25 mg/kg BW generated sustained and therapeutically active levels of Baytril in the aqueous humour of chickens' eyes.

Baytril is available as an injectable solution, oral syrup, or tablets.
The oral syrup should be given directly to the mouth or dissolved in the drinking water.
Due to its bitter taste, Baytril may be necessary to mix the drug with another medium such as applesauce or fruit juice to improve the taste.

The drug is less effective when administered in drinking water.
Baytril is an antibiotic in the fluoroquinolone family that is a good choice for a variety of infections.

Considered a broad-spectrum antibiotic, Baytril is often considered more of a “big gun” antibiotic, often reserved for more serious or resistant infections such as Pseudomonas.
Bacterial resistance is a growing concern in medicine and one reason fluoroquinolones as a class should be used judiciously.

Baytril is a fluoroquinolone antibiotic used to treat bacterial infections.
Baytril's use in dogs and cats to treat certain infections and its use in small mammals, birds, and reptiles is “off label” or “extra label”.

Many drugs are commonly prescribed for off-label use in veterinary medicine.
In these instances, follow your veterinarian’s directions and cautions very carefully, as their directions may be significantly different from those on the label.

Baytril is a quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7.
Baytril is a veterinary antibacterial agent used for the treatment of pets.

Baytril has a role as an antibacterial agent, an antineoplastic agent and an antimicrobial agent.
Baytril is a quinolinemonocarboxylic acid, a quinolone, an organofluorine compound, a N-alkylpiperazine, a N-arylpiperazine and a member of cyclopropanes.

Baytril is an antibiotic agent from the fluoroquinolone family produced by the Bayer Corporation.
Baytril is approved by the FDA for its veterinary use.

Due to the identification of fluoroquinolone-resistant strains of Campylobacter, in September 2005, the FDA withdrew the approval of Baytril for its use in water to treat flocks of poultry.
Baytril is a small molecule drug with a maximum clinical trial phase of II.

Baytril is a fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice.
Baytril is a member of the family of 6-fluoro-7-piperazinyl-4-quinolones.

Baytril is highly lipophilic, and the addition of a carboxic acid and a tertiary amine contributes to the amphoteric properties of Baytril.
Baytril is bactericidal and has excellent activity against both Gram-positive and Gram-negative pathogens.

Baytril is a broad-spectrum antibiotic commonly prescribed by veterinarians to treat dogs and cats with certain bacterial infections.
Baytril belongs to a class of antibiotics known as fluoroquinolones (quinolone carboxylic acid derivatives) which is designed to treat against Gram-negative and Gram-positive bacteria.

Baytril is not an appropriate treatment option against infections caused by viruses, fungi, or parasites.
Baytril is typically given orally and is available in tablet, capsule, and oral suspension forms.

Baytril is also available to veterinarians in an injectable form.
Baytril is available by prescription from your veterinarian or with a veterinary prescription.

Baytril is available in tablet, flavored chewable tablet, and injectable forms.
Baytril is bactericidal, with activity against both Gram negative and Gram positive bacteria.

The minimum inhibitory concentrations (MICs) were determined for a series of 39 isolates representing 9 genera of bacteria from natural infections in dogs and cats, selected principally because of resistance to one or more of the following antibiotics: ampicillin, cephalothin, colistin, chloramphenicol, erythromycin, gentamicin, kanamycin, penicillin, streptomycin, tetracycline, triple sulfa and sulfa/trimethoprim.

Most strains of these organisms were found to be susceptible to Baytril in vitro but the clinical significance has not been determined for some of the isolates.
The susceptibility of organisms to Baytril should be determined using Baytril 5 mcg disks.

Specimens for susceptibility testing should be collected prior to the initiation of Baytril therapy.
Baytril is a medicine used to treat certain infections in dogs and cats.
Baytril is also used “extra-label” or “off-label” for other infections in dogs and cats.

Medicines can be prescribed “extra-label” or “off-label” in veterinary medicine in certain situations where there is no approval from the Food and Drug Administration (FDA) but there is evidence of safe and effective use.
Baytril is classified as a fluoroquinolone antibiotic that has a broad spectrum of activity, meaning it is effective against many types of bacteria.

Baytril, or 1-Cyclopropyl-6-fluoro-7-(4-ethyl-1-piperazinyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, belongs to fluoroquinolone family which is a subfamily of quinolone.
The first quinolone is the Nalidixic acid used in animal at the beginning of 1980s.

Baytril is the first fluoroquinolone patented in 1984.
The huge evolution in the quinolone family is the addition of a fluor atom on the 6th position which improves quinolones’ antibacterial spectrum and creates the fluoroquinolone subfamily.

Quinolones have an action on bacterial topoisomerase.
The marketing authorization reports a large antimicrobial spectrum for Baytril, which is efficient on most gram-negative and gram-positive bacteria but not efficient on anaerobic bacteria.

But with 3.6 tons sold per year in France for animal use, fluoroquinolones are an important family in veterinary medicine that increases the probability of selecting resisting bacteria.
Baytril is a fluoroquinolone antibiotic used for the treatment of animals.

Baytril is a bactericidal agent.
The bactericidal activity of Baytril is concentration-dependent, with susceptible bacteria cell death occurring within 20–30 minutes of exposure.

Baytril has demonstrated a significant post-antibiotic effect for both Gram-negative and Gram-positive bacteria and is active in both stationary and growth phases of bacterial replication.
Baytril is partially deethylated by CYP450 into the active metabolite ciprofloxacin, which is also a fluoroquinolone antibiotic.

In September 2005, the FDA withdrew approval of Baytril for use in water to treat flocks of poultry, as the practice was noted to promote the evolution of fluoroquinolone-resistant strains of the bacterium Campylobacter, a human pathogen.

Baytril is available as a fixed-dose combination medication with silver sulfadiazine for the treatment of canine otitis externa.
Baytril is available as a generic medication.

Baytril is a synthetic, broad-spectrum fluoroquinolone antibiotic primarily developed for veterinary use.
Baytril is structurally related to ciprofloxacin, a major fluoroquinolone used in human medicine, and shares the same core mechanism of action.

Baytril exerts its antibacterial effect by selectively inhibiting two key bacterial enzymes: DNA gyrase and topoisomerase IV.
These enzymes are responsible for maintaining DNA supercoiling and for the proper separation of replicated chromosomes during bacterial cell division.

When inhibited, DNA synthesis and cell replication are disrupted, ultimately leading to bacterial cell death.
This mechanism makes Baytril bactericidal rather than merely bacteriostatic, providing rapid and reliable clearance of infections.

Pharmacologically, Baytril is valued for its broad-spectrum activity, covering many Gram-negative bacteria (such as Escherichia coli, Salmonella spp., and Pasteurella multocida) and Gram-positive bacteria (such as Staphylococcus aureus).
Baytril is particularly effective in treating respiratory tract infections, urinary tract infections, skin and soft tissue infections, gastrointestinal infections, and certain systemic septicemias in animals.
In addition, Baytril has some activity against Mycoplasma species, which are important respiratory pathogens in poultry and cattle.

The drug is available in several formulations depending on the target animal and clinical use, including oral tablets, injectable solutions, and soluble powders for administration via drinking water or feed.
This versatility allows Baytril to be widely applied across species such as dogs, cats, cattle, swine, and poultry.
In companion animals, Baytril is often prescribed for persistent or resistant infections, while in food-producing animals, its use is carefully controlled due to concerns about drug residues and resistance development.

Pharmacokinetically, Baytril is well absorbed after oral or parenteral administration, demonstrating high bioavailability and good tissue penetration, particularly into the lungs, kidneys, liver, and skin.
In many species, a portion of Baytril is metabolized into ciprofloxacin, which also possesses potent antibacterial activity, thereby enhancing the overall therapeutic effect.

However, the use of Baytril is not without challenges and restrictions.
One of the major concerns is the potential for antimicrobial resistance.

Since fluoroquinolones are critically important in human medicine, the emergence of resistance in zoonotic bacteria (e.g., Salmonella and Campylobacter) can pose significant public health risks.
Regulatory agencies such as the FDA (U.S.) and EMA (Europe) have issued strict guidelines for its use, including restrictions in certain food-producing animals and clearly defined withdrawal periods to ensure that no harmful residues remain in meat, milk, or eggs destined for human consumption.

Clinically, Baytril is generally well tolerated, but some adverse effects may occur.
In dogs, high doses have been associated with retinal degeneration leading to blindness, especially in sensitive breeds.

Gastrointestinal upset (vomiting, diarrhea) may also occur in some animals.
In young, growing animals, fluoroquinolones can cause articular cartilage damage, which is why their use is often restricted in immature animals unless no safer alternative exists.

Since its introduction in the late 1980s, Baytril has become a cornerstone in veterinary antimicrobial therapy, valued for its efficacy, tissue distribution, and broad coverage.
At the same time, Baytril's history illustrates the delicate balance between effective veterinary care and the global effort to preserve antibiotic efficacy for both animals and humans.

Market Overview of Baytril:
Baytril occupies a significant position in the global veterinary pharmaceuticals market, particularly within the antimicrobial and anti-infective segment.
Baytril has become one of the most widely recognized fluoroquinolone antibiotics for veterinary use worldwide.
Baytril's adoption was driven by its broad-spectrum efficacy, relatively low frequency of resistance (at the time of introduction), and its versatility in treating both companion animals and food-producing livestock.

The demand for Baytril is shaped by the dual growth of the companion animal care industry and the livestock production sector.
In companion animals, increasing pet ownership, rising expenditures on veterinary care, and greater awareness of infectious disease management have supported steady sales of Baytril-based formulations such as tablets and injectables.

In livestock and poultry, Baytril gained popularity due to its effectiveness against respiratory, enteric, and systemic infections, which directly impact productivity, feed conversion efficiency, and mortality rates.
Baytril's inclusion in herd- and flock-level treatments (via medicated water or feed) made it a valuable tool for intensive animal production systems.

However, the market dynamics have shifted significantly in recent years due to antimicrobial resistance concerns and regulatory restrictions:
In the United States, the FDA withdrew approval for the use of Baytril in poultry in 2005, citing the risk of fluoroquinolone-resistant Campylobacter transmission to humans.

In the European Union, Baytril remains approved but is subject to strict regulation, with mandatory withdrawal times for meat, milk, and eggs, and guidelines to limit its prophylactic and growth-promotion use.
In emerging markets such as Asia-Pacific and Latin America, demand remains robust due to high levels of livestock production and limited alternatives in certain veterinary contexts, although regulatory scrutiny is increasing.

The global Baytril market is thus in a transitional phase: while its importance as a therapeutic agent persists, its growth potential is increasingly constrained by regulatory limitations and the rising emphasis on antibiotic stewardship.
As a result, many veterinary pharmaceutical companies are investing in next-generation antimicrobials, vaccines, and alternative treatments to reduce reliance on fluoroquinolones, while Baytril continues to hold a strong—though more carefully managed—position in both developed and developing markets.

Uses of Baytril:
Baytril is a broad spectrum treatment that helps treat bacterial infections such as Paratyphoid, Mycoplasma, and Salmonella/E.coli.
Safe to use on pet birds such as finches, canaries, pigeons, backyard chickens, and even pet rats.

If you believe your pet has developed a bacterial infection, your pet should be seen by a veterinarian as soon as possible.
Medications are available that can quickly resolve the infection and get your pet back to good health.

Depending on your pet’s diagnosis, Baytril may be the antibiotic your veterinarian prescribes because it is effective against a variety of infections.
Baytril is a fluoroquinolone antibiotic, which has proven to be highly effective against a wide range of bacterial types.

This includes some of the more difficult to treat infections.
Baytril prevents bacterial cells from replicating and rapidly causes cell death.

Gram-positive coverage is limited and often includes Staphylococcus spp., but Baytril is not effective against Enterococcus spp.
Baytril is commonly used to treat respiratory, urinary tract, and skin (dermal) infections.

Baytril has also been used to control certain intracellular pathogens.
Baytril is employed extensively in veterinary medicine due to its broad-spectrum antibacterial properties and reliable pharmacological profile.

Baytril's main applications can be divided into companion animal care and livestock/poultry production:

Companion Animals (Dogs & Cats):
Respiratory infections (e.g., bronchitis, pneumonia caused by Pasteurella, Bordetella, Streptococcus spp.)
Urinary tract infections (UTIs) caused by E. coli, Proteus, and other Enterobacteriaceae

Skin and soft tissue infections including wounds, abscesses, and pyoderma
Otitis externa and media, particularly where Pseudomonas aeruginosa is involved

Gastrointestinal infections, especially those caused by enteric Gram-negative bacteria
Septicemia and systemic infections, when broad-spectrum rapid action is required
Baytril is valued in pets because of its high oral bioavailability, ease of dosing, and ability to penetrate tissues deeply, ensuring effectiveness in both acute and chronic infections.

Livestock (Cattle, Swine, Sheep, Goats):
Bovine respiratory disease complex (BRDC) caused by Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni
Swine respiratory disease involving Actinobacillus pleuropneumoniae and Mycoplasma hyopneumoniae

Enteric diseases such as colibacillosis (E. coli) in calves and piglets
Mastitis and metritis in cattle, although extra-label use may be restricted in some regions

Baytril is frequently administered as an injectable solution in large animals, offering rapid systemic levels during acute disease outbreaks.
Poultry (Broilers, Layers, Turkeys, Ducks):

Control of colibacillosis (E. coli infections)
Treatment of chronic respiratory disease due to Mycoplasma spp.

Management of fowl cholera caused by Pasteurella multocida
Therapy against systemic septicemic infections

In poultry, Baytril was once widely used through medicated drinking water, making it cost-effective for flock-level treatment.
However, Baytril's use has been restricted or banned in several countries due to public health concerns.

Other Applications:
Treatment of fish and aquaculture diseases in some countries, though this is controversial due to ecological risks and residue concerns.
Use in exotic animals and zoo medicine, including reptiles and birds, where resistant infections are difficult to manage.

Cats:
Baytril is used in dermal infections (wounds and abscesses) associated with susceptible strains of Pasteurella multocida, Staphylococcus aureus, and Staphylococcus epidermidis.
Baytril is especially good against Gram-negative bacteria that other antibiotics can’t kill.

Baytril is best to save this broad-spectrum antibiotic for the infections that other antibiotics can’t fight.
This is one step in limiting antibiotic resistance, which means that the bacteria can withstand antibiotics.
In dogs, Baytril is approved by the FDA for oral and intramuscular (injection into the muscle) use.

Baytril can also be used extra-label in dogs by injection subcutaneously (under the skin) or intravenously (into a vein), but this is controversial.
In cats, only the oral form is FDA-approved, but the injectable form is sometimes used extra-label either intramuscularly or intravenously.

Baytril, a fluoroquinolone antibiotic, is widely employed in veterinary medicine, particularly in dogs and cats, to combat bacterial infections.
Baytril's mechanism of action involves inhibiting bacterial DNA gyrase and topoisomerase IV, critical enzymes in DNA replication and repair, leading to the disruption of bacterial growth and eventual cell death.

Effective against a broad spectrum of Gram-negative and Gram-positive bacteria, Baytril is commonly used to treat various infections, including those affecting the respiratory, urinary, and integumentary systems in animals.
Baytril is crucial to adhere to veterinary prescriptions and complete the recommended course of treatment to ensure the successful eradication of bacterial infections, although its use in food-producing animals may be restricted due to concerns about antibiotic resistance.

Baytril is used for the treatment and control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, Streptococcus suis, Bordetella bronchiseptica, and Mycoplasma hyopneumoniae (M. hyo).
For the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with Escherichia coli (E. coli) has been diagnosed.

Dogs:
Baytril is used to treat dermal infections (wounds and abscesses) associated with susceptible strains of Escherichia coli (E. coli), Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus intermedius; respiratory infections (pneumonia, tonsillitis, rhinitis) associated with susceptible strains of Escherichia coli and Staphylococcus aureus; and urinary cystitis associated with susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus aureus.
Baytril is generally used as a second-line drug for the treatment of deep pyoderma in dogs, although use is only recommended if culture and susceptibility results indicate first-line drugs will not be effective.

Benefits of Baytril:
Baytril offers multiple clinical and practical benefits that explain its widespread adoption in veterinary medicine since the late 1980s.

These advantages are observed across both companion animal care and livestock production systems:

Broad-Spectrum Efficacy:
Active against a wide range of Gram-negative and Gram-positive bacteria, including E. coli, Pasteurella spp., Staphylococcus spp., Pseudomonas spp., and Mycoplasma spp.
Effective for mixed infections, where pathogens of different bacterial groups coexist.
Bactericidal mode of action ensures rapid elimination rather than just inhibition.

Rapid Onset and Reliable Action:
Demonstrates fast absorption and high bioavailability, especially after oral administration.
Provides rapid therapeutic levels in blood and tissues, making it suitable for acute infections.
Consistent and predictable pharmacokinetics across multiple species.

Deep Tissue Penetration:
Baytril distributes efficiently into lungs, kidneys, liver, skin, and soft tissues, ensuring effectiveness in systemic and localized infections.
Ability to cross barriers into respiratory and urinary systems, which are common infection sites in animals.

Versatile Administration Options:
Available in oral tablets, injectable solutions, and soluble powders for drinking water/feed.
Allows both individual treatment (e.g., in dogs and cats) and herd/flock-level therapy (e.g., in poultry and swine).
Once-daily dosing improves treatment compliance for pet owners and livestock managers.

Economic and Productivity Benefits in Livestock:
Reduces mortality and morbidity in herds and flocks affected by respiratory or enteric disease.
Improves feed efficiency, growth rates, and overall animal welfare, lowering economic losses in intensive production systems.
Valuable in outbreak situations, where rapid control of infection prevents spread.

Synergistic Metabolite (Ciprofloxacin):
Part of Baytril is metabolized into ciprofloxacin, a potent fluoroquinolone, thereby enhancing therapeutic impact and prolonging activity.

Broad Species Coverage:
Can be safely and effectively used in dogs, cats, cattle, swine, poultry, sheep, goats, reptiles, and exotic birds.
Increases Baytril's utility for veterinarians working across diverse animal species.

Pharmacokinetic of Baytril:

Absorption:
There is high variation of bioavailability after oral administration of Baytril between polygastric and monogastric animals from 10% to 80%.

This has direct consequences on the galenic; oral presentations are reserved for pigs, poultry, calves, and carnivores, and only injectable solutions are available for cattle.
Moreover, bioavailability depends on whether the animals are fed or fasted, and on the presence of ions.

These interferences can be explained by the formation of a complex between cation and fluoroquinolone which cannot permeate through the digestive barrier.
Another consequence of this complex is the influence of the hardness of water, notably in poultry farming where the dilution in water is used.
Lipophilic compounds in food can enhance the oral bioavailability of fluoroquinolone.

In addition to passive diffusion allowed by Baytril’s lipophilicity, active transporters also have an important role in intestinal absorption.
These transporters are also important for the elimination of fluoroquinolones.

The intramuscular bioavailability is 96%, with a maximum concentration 3 hours after administration.
Intramuscular bioavailability can be enhanced by solid lipophilic nanoparticles; this technique enhances the duration of Baytril in plasma.

Metabolism:
After administration, a high part of Baytril is metabolized into ciprofloxacin in most species.
Baytril has an active metabolite, ciprofloxacin, obtained by deethylation of the ethyl group on the piperazine ring.
Other metabolites are obtained, but they do not have antimicrobial effects.

Only poultry does not have a large portion of Baytril metabolized into ciprofloxacin.
The first hepatic pass does not have a significant effect; only 7% of Baytril is metabolized.

Moreover, ciprofloxacin seems to be a more potent drug than Baytril.
These elements support granting a more important role to ciprofloxacin in the effects of Baytril-based drugs.

Distribution:
Distribution of Baytril and ciprofloxacin to tissues depends on the drug’s free concentration, which itself depends on protein concentration and the strength of binding.
The difference between ciprofloxacin and Baytril protein binding supports the theory of Baytril acting as a prodrug.

In some species, ciprofloxacin is less bound to proteins, making it more available to be effective.
Moreover, Baytril can interact with other protein-binding drugs; for instance, it increases the clearance of flunixin meglumine.

The volumes of distribution of Baytril and ciprofloxacin in different species are all higher than 1.
So, Baytril and its metabolite diffuse strongly in tissues, and molecules can be present in cells, rendering them inactive.

Contrary to expectations based on protein binding, ciprofloxacin does not diffuse in tissues more than Baytril.
Suggest a high affinity of the drugs for the lungs and kidneys, even though data confirm Baytril’s and ciprofloxacin’s good diffusion.

Baytril is an antibiotic agent from the fluoroquinolone family produced by the Bayer Corporation.
Baytril is approved by the FDA for its veterinary use.

Due to the identification of fluoroquinolone-resistant strains of Campylobacter, in September 2005, the FDA withdrew the approval of Baytril for its use in water to treat flocks of poultry.

Production of Baytril:
Baytril is produced through a multi-step synthetic process characteristic of the fluoroquinolone class, beginning with substituted anilines and carboxylic acids to form the quinolone nucleus, followed by fluorination at the 6-position, substitution with a piperazinyl group, and introduction of an ethyl side chain that distinguishes it from ciprofloxacin.
These steps yield a highly lipophilic, broad-spectrum antibacterial agent suitable for veterinary use.

Industrial production is carried out mainly in pharmaceutical hubs such as China, India, and Europe, where the active pharmaceutical ingredient (API) is manufactured at scale and later formulated into tablets, injectables, or soluble powders.
All stages of production are governed by Good Manufacturing Practice (GMP) standards, with strict pharmacopeial specifications for purity, potency, and stability, as well as environmental controls to minimize the ecological impact of fluoroquinolone residues.
This combination of advanced synthetic chemistry and regulatory oversight ensures Baytril’s consistent quality, safety, and effectiveness in the global veterinary market.

History of Baytril:
Baytril was first developed by Bayer AG in the 1980s and introduced to the veterinary market in 1988, marking a major milestone in animal health because it was one of the first fluoroquinolones specifically designed for veterinary use.
Baytril's rapid success stemmed from its broad-spectrum activity, high tissue penetration, and reliable pharmacokinetics, which made it highly effective against respiratory, enteric, urinary, and systemic infections in both companion animals and livestock.

By the early 1990s, Baytril was approved and widely adopted across Europe, North America, and Asia, becoming a cornerstone antimicrobial in poultry and cattle production as well as small animal medicine.
However, as concerns over antimicrobial resistance grew, regulatory agencies began to limit its applications—most notably, the U.S. FDA banned its use in poultry in 2005 due to links with fluoroquinolone-resistant Campylobacter.
Despite these restrictions, Baytril remains one of the most important veterinary antibiotics worldwide, balancing decades of proven clinical value with ongoing efforts to preserve fluoroquinolone effectiveness for both animals and humans.

Handling and Storage of Baytril:

Handling:
Avoid direct contact with skin, eyes, and mucous membranes.
Work in well-ventilated areas or under local exhaust.

Do not eat, drink, or smoke while handling the substance.
Wash hands thoroughly after use.
Use appropriate protective equipment (gloves, goggles, lab coat).

Storage:
Keep in the original, tightly closed container.
Store in a cool, dry, and well-ventilated place away from direct sunlight, excessive heat, and moisture.

Protect from freezing.
Keep out of reach of children, pets, and unauthorized personnel.
Follow manufacturer’s shelf-life specifications.

Stability and Reactivity of Baytril:

Stability:
Stable under recommended storage and handling conditions.

Reactivity:
No hazardous polymerization expected.

Incompatible materials:
Strong oxidizing agents, strong acids, and alkalis may cause degradation.

Hazardous decomposition products:
Carbon oxides, nitrogen oxides, and toxic fluorinated compounds may be released during fire or thermal decomposition.

First Aid Measures of Baytril:

Inhalation:
Move the exposed person to fresh air.
If symptoms (cough, difficulty breathing) persist, seek medical attention.

Skin contact:
Wash immediately with soap and water.
Remove contaminated clothing.
If irritation occurs, get medical advice.

Eye contact:
Rinse cautiously with water for at least 15 minutes, keeping eyelids open.
Seek medical attention if irritation persists.

Ingestion:
Rinse mouth with water.
Do not induce vomiting.
Seek immediate medical assistance and show the product label/packaging.

Note to physician:
Symptomatic treatment.
Monitor for allergic reactions or gastrointestinal effects.

Firefighting Measures of Baytril:

Suitable extinguishing media:
Water spray, dry chemical powder, carbon dioxide (CO₂), or foam.

Unsuitable media:
Direct high-volume water jets (may spread contamination).

Specific hazards:
Decomposition may release toxic fumes (fluorine compounds, nitrogen oxides).

Protective equipment:
Firefighters should wear full protective clothing and self-contained breathing apparatus (SCBA).

Accidental Release Measures of Baytril:

Personal precautions:
Wear PPE including gloves, protective clothing, and a respirator if dust or aerosols are generated.
Avoid breathing vapors/dust.

Environmental precautions:
Prevent spillage from entering drains, soil, or waterways, as fluoroquinolones may cause ecological harm.

Spill cleanup:
Absorb liquid spills with inert material (sand, vermiculite).
Collect solids mechanically and place in suitable containers for disposal.

Wash contaminated area with water and detergent.
Dispose of waste according to local regulations.

Exposure Controls / Personal Protection of Baytril:

Engineering controls:
Provide adequate ventilation or local exhaust.
Use fume hoods when handling powders in laboratory settings.

Personal Protective Equipment

Respiratory:
Dust mask or respirator (NIOSH/EN-approved) if airborne particles may form.

Skin:
Nitrile or latex gloves; long-sleeved protective clothing.

Eyes/face:
Safety goggles or face shield.

Hygiene measures:
Wash hands after handling.
Remove contaminated clothing before reuse.

Identifiers of Baytril:
IUPAC Name: 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid
Common Name: Baytril
CAS Number: 93106-60-6
EC Number (EINECS): 618-571-2
PubChem CID: 71188
UNII (FDA Unique Ingredient Identifier): A5R0RZP4ZO
ATCvet Code: QJ01MA90 (antibacterials for systemic use, fluoroquinolones)
Chemical Formula: C₁₉H₂₂FN₃O₃
Molecular Weight: 359.40 g/mol
InChI Key: WVCVHZZTPLCDJE-UHFFFAOYSA-N
Structure: Fluoroquinolone skeleton with cyclopropyl at N-1, fluorine at C-6, ethylpiperazine substituent at C-7, and carboxylic acid at C-3.

IUPAC Name: 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid
Common Name: Baytril
CAS Number: 93106-60-6
EC Number (EINECS): 618-571-2
PubChem CID: 71188
ChEBI ID: CHEBI:47968
DrugBank ID: DB11404 (veterinary use)
UNII (FDA): A5R0RZP4ZO
ChemSpider ID: 64308
KEGG Drug ID: D04145
ATCvet Code: QJ01MA90 (systemic antibacterial, fluoroquinolone group)

Molecular Formula: C₁₉H₂₂FN₃O₃
Molecular Weight: 359.40 g/mol
InChI: InChI=1S/C19H22FN3O3/c1-2-22-6-8-23(9-7-22)18-10-15-16(20)11-13(18)12(19(25)26)14(24)17(15)21-5-3-4-21/h10-11H,2-9H2,1H3,(H,25,26)
InChI Key: WVCVHZZTPLCDJE-UHFFFAOYSA-N
SMILES: CCN1CCN(CC1)C2=C(C=C3C(=C2F)C(=O)C(=CN3)C4CC4)C(=O)O

Properties of Baytril:
Chemical Formula: C₁₉H₂₂FN₃O₃
Molecular Weight: 359.40 g/mol

Appearance:
Off-white to pale yellow crystalline powder
Odorless or faint characteristic odor

Physical State: Solid (powder/crystals), often formulated into tablets, suspensions, or injectable solutions for veterinary use
Melting Point / Range: ~ 218–221 °C (with decomposition)

Solubility:
Slightly soluble in water (~100 mg/L at 25 °C, pH-dependent)
Freely soluble in dilute acids (e.g., hydrochloric acid)
Soluble in some polar organic solvents (methanol, ethanol, DMSO)
Solubility increases significantly at acidic pH due to protonation of the piperazine group

Molecular Weight: 359.4 g/mol
XLogP3: -0.2
Hydrogen Bond Donor Count: 1
Hydrogen Bond Acceptor Count: 7
Rotatable Bond Count: 4
Exact Mass: 359.16451973 Da
Monoisotopic Mass: 359.16451973 Da
Topological Polar Surface Area: 64.1 Å²
Heavy Atom Count: 26
Complexity: 613
Isotope Atom Count: 0
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count: 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Covalently-Bonded Unit Count: 1
Compound Is Canonicalized: Yes

Empirical Formula (Hill Notation): C19H22FN3O3
Beilstein: 5307824
MDL number: MFCD00792463
UNSPSC Code: 41116105
PubChem Substance ID: 329751571
NACRES: NA.21
Physical state: powder, crystals
Melting point/freezing point: Melting point/ range: 219 - 221 °C

Odor: Musty, characteristic for quinolones
Melting Point: 219–225 °C
Boiling Point: ~560 °C (estimated)
Density: ~1.385 g/cm³
Solubility: Slightly soluble in water, soluble in chloroform and dilute KOH
pKa: ~6.4
Log P: Not available, but hydrophilicity moderate due to ionizable carboxyl group
Stability: Stable under normal conditions;
may form explosive dust-air mixtures when handled as a dry powder; avoid strong oxidizers